CD133 Expression in Normal Skin and in Epithelial Cutaneous Tumors

Table 1

Summary of clinical and immunohistochemical findings.

Diagnosis	Age	Location	CD133
Eccrine spiradenoma (𝑛=3)	76	Nasal	+++
	52	Neck	+++
	58	Nasal	++
Hidradenoma (𝑛=5)	38	Unknown	+++
	77	Forehead	+++
	85	Face	+++
	48	Head	++
	78	Unknown	++
Eccrine hidrocystoma (𝑛=3)	76	Nasal	+++
	52	Neck	++
	58	Nasal	+++
Poroma (𝑛=6)	34	Plantar	++
	85	Forearm	+++
	51	Scalp	+++
	31	Leg	+
	59	Unknown	+++
	67	Unknown	++
Porocarcinoma (𝑛=1)	90	Back	+++
Syringocystadenoma papilliferum (𝑛=3)	36	Scalp	++
	60	Pectoral	+++
	28	Scalp	+++
Syringoma (𝑛=6)	42	Unknown	+
	36	Forearm	++
	32	Neck	+
	31	Eyelid	+
	67	Inferior eyelid	−
	36	Eyelid	++
Cylindroma (𝑛=4)	51	Scalp	++
	51	Scalp	+++
	80	Scalp	++
	47	Unknown	+++
Hidradenoma papilliferum (𝑛=2)	75	Vulvar	+
	31	Vulvar	+
Chondroid syringoma (𝑛=4)	38	Supralabial	++
	36	Nasal	+++
	60	Forehead	+++
	53	Eyelid	+++
Apocrine hidrocystoma (𝑛=3)	33	Eyelid	−
	79	Eyelid	−
	40	Face	−
Apocrine carcinoma (𝑛=1)	62	Axilar	−
Microcystic adnexal carcinoma (𝑛=2)	46	Upper lip	+++
	53	Upper lip	+++

CD133 staining was graded using a semiquantitative scale. Acinar or ductal structures were evaluated as follows: (−) no staining; (+) staining of secretory material in the lumen of isolated ductules or acini and/or weak staining of the apical or luminal border of few ductules or acini; (++) clear staining of the apical or luminal border of most ductules or acini present in the tumour; (+++) staining of the apical or luminal border of all ductules or acini present in the tumor.